ライフサイエンス企業情報プラットフォーム

AGC株式会社

AGCグループはグローバルにバイオ医薬品原薬の受託開発・製造事業を展開しています。豊富な実績と高度な技術に基づき、バイオ医薬品原薬の開発段階から商用段階までをサポートしています。

会社カテゴリー:原薬・添加剤・中間体、製造受託機関(CMO)、医薬品製造、再生医療関連

主サービス提供地域:日本、アメリカ合衆国、ヨーロッパ(イギリス以外)、イギリス、アジア

製品・サービス詳細

掲載日:2022/08/19

掲載日:2022/08/19

ウイルスベクター開発製造サービス

サービスカテゴリー:モダリティ

AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV) and retroviral vectors (RVV). The AGC Biologics viral vector program at our flagship Milan site has supported three commercial products to-date.

Our ready-to-use platform capabilities are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house. 

Our quality systems, manufacturing scales, and regulatory expertise allow us to meet both clinical and commercial viral vector demands. Moreover, our scale-down capabilities provide flexible and cost-effective solutions for process development and pre-clinical studies. 

Viral Vector Production and Manufacturing Services  

  • Viral Vector services including development, characterization, and manufacturing (PD/cGMP environment)

  • Small, medium, and large-scale equipment for both adhesion and suspension-based processes

  • A plug-and-play platform for large-scale vector manufacturing that can be adapted to virtually any program

  • A reliable and flexible platform for various scales of AAV production with different serotypes

  • cGMP viral vector manufacturing at various scales across up to 2,000L across two global sites

  • 160+ in-house analytical tests with custom designs for clinical and commercial supply

  • Global quality systems and teams of scientists with two decades of global regulatory experience in the cell and gene field